Edgestream Partners, L.P. Halozyme Therapeutics, Inc. Transaction History
Edgestream Partners, L.P.
- $2.23 Billion
- Q3 2024
A detailed history of Edgestream Partners, L.P. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Edgestream Partners, L.P. holds 86,001 shares of HALO stock, worth $4.09 Million. This represents 0.22% of its overall portfolio holdings.
Number of Shares
86,001
Previous 39,649
116.91%
Holding current value
$4.09 Million
Previous $2.08 Million
136.99%
% of portfolio
0.22%
Previous 0.1%
Shares
9 transactions
Others Institutions Holding HALO
# of Institutions
543Shares Held
125MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$838 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$613 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$315 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$193 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$162 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $6.62B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...